Clinical Trials Logo

Clinical Trial Summary

This cross-sectional survey study is to determine the prevalence of functional gastrointestinal (GI) disorders in the general population and to describe common triggers for food-related GI symptoms.


Clinical Trial Description

Functional gastrointestinal disorders, involving symptoms such as gas/bloating, diarrhea, constipation and abdominal pain, are estimated to impact between 35 and 45 million Americans, an overwhelming 15-20% of the population. These symptoms are responsible for upwards of 20 billion dollars in healthcare costs and extensive loss of quality of life for sufferers. Moreover, many patients suffer in silence, with 67% of subjects waiting more than a year before treatment, and 11% waiting over 10 years. Irritable bowel syndrome is the most prevalent functional gastrointestinal disorder, and several recent studies support the idea that dietary modifications may be key to alleviating this condition.

The purpose of this study is to document gastrointestinal symptoms among the US population, as well as to ascertain awareness and utilization of dietary treatments that exist. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03102411
Study type Observational
Source TriHealth Inc.
Contact
Status Completed
Phase
Start date March 9, 2017
Completion date September 15, 2017

See also
  Status Clinical Trial Phase
Completed NCT03269617 - PHAGE Study: Bacteriophages as Novel Prebiotics N/A
Terminated NCT02974686 - Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation Phase 4
Active, not recruiting NCT05363553 - Transition to Infant Formula Feeding on Gastrointestinal Regurgitation (TIGER) Study N/A
Completed NCT04530929 - Analysis of the Impact of Used Probiotic Strains and Diet on Body Composition, Cardiopulmonary Efficiency and the Incidence of Gastrointestinal Disorders in Runners N/A
Withdrawn NCT03014141 - Effect of Oat Bran on Bowel Function and Appetite N/A
Completed NCT05915767 - Therapeutic Effect of Olive Leaf Tea on SIBO N/A
Recruiting NCT03011151 - Protease Activated Receptor-2 and Gastrointestinal Dysfunction in Critical Illness